{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 28,
  "pageCount": 36,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/28",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-28",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The figures for the cardiovascular endpoint have also been manipulated: Though the SONAR study acknowledges 31 cardiovascular deaths in the drug group and 28 in the placebo group among responders, along with 47 hospital admissions for heart failure in the drug group and only 34 in placebo among responders, it then makes use of two strange calculations to arrive at its cardiorenal and cardiovascular composite endpoints.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-4dacf7fdef34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.685,
        "w": 0.764,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "paragraph",
      "text": "The text argues that composite endpoints in the SONAR study are misleading and that Chinook has inconsistently reported patient counts in its own AFFINITY and ALIGN trials.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6515267-d534-4cc8-85dd-94b9a52073ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Atrasentan has previously demonstrated clinically significant and sustained proteinuria reduction with an acceptable safety profile in over 5,100 patients with diabetic kidney disease (DKD). — Chinook Therapeutics (Interim results from AFFINITY)",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-5202d40ba9b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.125,
        "w": 0.764,
        "x": 0.118,
        "y": 0.793
      },
      "kind": "source-note",
      "text": "Footnotes 138-145 detailing sources for clinical trial data and presentations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f14402de-2d5f-4fab-80a1-f9c8b804ebe2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.563,
        "x": 0.118,
        "y": 0.548
      },
      "kind": "title",
      "text": "Chinook Misled Investors on Past and Current Research",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d92961e4-a359-4ff9-ad97-07f5f8fef9f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "ecb9fa43-ca09-4bc2-b958-440d609e9add",
      "evidence": "The slide explicitly accuses the company of misleading investors regarding clinical trial data and methodology.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 33,
      "from": 28,
      "beatId": "640ed796-f0a7-4d27-b017-41863f0ffedf",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The report presents the 'victory' of Muddy Waters Research in uncovering the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 28,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6980f318-c257-42fa-96be-f6e3de335b06",
      "evidence": "The report implies that investors and analysts should be cautious",
      "position": 1,
      "objective": "To highlight the consequences of not addressing the issues with the trial results",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}